The purpose is to assess the influence of the level of the biomarker Galectin-3 in the blood on the clinical and functional state and hemodynamic parameters of patients with coronary artery disease complicated by CHF in Post-COVID 19 Period. Material and research methods. 70 patients with CHF against the background of stable coronary artery disease were examined: 36 patients with coronary artery disease / CHF who had undergone COVID-19 were included in group I, and 34 patients with coronary artery disease / CHF without COVID-19 in the anamnesis were included in group II studied. The assessment of the clinical and functional state of CHF was carried out using the six-minute walk test (SMWT) and according to the scale for assessing the clinical state (SACS). The level of fibromarker Gal-3 in blood serum was assessed by the method of enzyme-linked immunosorbent assay (ELISA) ELISA. Results. The results obtained during the study indicate the unfavorable effect of an increased level of the biomarker of fibrosis Galectin-3 on the clinical and functional state and hemodynamic parameters of patients with coronary artery disease complicated by CHF against the background of the transferred COVID-19, this adverse effect of which persists in the postcovid period. Also, a key mediator of fibrotic and proliferative processes, Galectin-3, can serve as a predictor not only for postcovid complications, but also for the development and progression of CHF with preserved systolic function due to coronary artery disease. Conclusion. Thus, Galectin-3, a key mediator of fibrotic and proliferative processes, can serve as a specific biomarker for early diagnosis of the development of severe CHF and cardiovascular complications in CHD patients who have undergone COVID-19 in the post-covid period.
1. Aspromonte N., Gulizia M.M. et al. ANMCO/ELAS/SIBioC Consensus Document: Biomarkers in heart failure. Eur. Hear. J. Suppl. 2017, 19 (Suppl. D), D102–D112. 2. Agnello L., Bellia C., Sasso B.L., et al. Establishing the upper reference limit of Galectin-3 in healthy blood donors. Biochem. Med. 2017, 27, 030709 3. Aksan G., Gedikli Ö., Keskin K. et al. Is galectin-3 a biomarker, a player—or both—in the presence of coronary atherosclerosis? J. Investig. Med. 2016, 64, 764–770. 4. Anand I.S., Rector T.S. et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT // Eur. J. Heart Fail. – 2013. – Vol. 15 (5). – P. 511-518 5. Biasi D. S., Meschiari M., Gibellini L., Bellinazzi C., Borella R., Fidanza L, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. 2020, 11:3434. doi: 10.1038/s41467-020-1729 6. Boza-Serrano A., Ruiz R., Sanchez-Varo R. et al. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease. Acta Neuropathol. 2019, 138:251–73. doi: 10.1007/s00401-019-02013-z. 7. Burguillos M.A., Svensson M., Schulte T. et al. Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep. 2015,- 10:1626–38. doi: 10.1016/j.celrep.2015.02.012 8. Ho J.E., Gao W., Levy D., Santhanakrishnan R., Araki T., Rosas I.O. et al. Galectin-3 is associated with restrictive lung disease and interstitial lung abnormalities. Am J Respir Crit Care Med. 2016, 194:77–83. doi: 10.1164/rccm.201509-1753OC 9. Hara A., Niwa M., Noguchi K., Kanayama T., Niwa A., Matsuo M, et al. Galectin-3 as a next-generation biomarker for detecting early stage of various diseases. Biomolecules. 2020,- 10:389. doi: 10.3390/biom10030389 10. Juan Garcia-Revilla, Tomas Deierborg, Jose Luis Venero et al. Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider. Front. Immunol., 18 August 2020. 11. Sato S., Ouellet N., Pelletier I., Simard M., Rancourt A., Bergeron M.G. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol. 2002,- 168:1813–22. doi: 10.4049/jimmunol.168.4.1813 12. Shah R. V., Chen-Tournoux A. A., Picard M. H. et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. European Journal of Heart Failure, 2010; 12(8), 826–832. 13. Ten Oever J., Giamarellos-Bourboulis E.J., van de Veerdonk F.L., Stelma F.F., Simon A., Janssen M., et al. Circulating galectin-3 in infections and non-infectious inflammatory diseases. Eur J Clin Microbiol Infect Dis. 2013,- 32:1605–10. 14. Wu A.H. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results / A.H. Wu, F. Wians, A. Jaffe // Am. Heart J. – 2013. – Vol. 165 (6). – P. 995-999. 15. Yorulmaz H., Ozkok E., Kaptan E., Ates G., Tame S. Therapeutic effects of simvastatin on Galectin-3 and oxidative stress parameters in endotoxemic lung tissue. Biosci Rep. 2018, 38:3. doi: 10.1042/bsr20180308.
Nurillaeva, Nargiza М.; Odilovna, Dildora N.; and Abdumalikova, Feruza B.
"PREDICTIVE ROLE OF FIBROMARKER GALECTIN-3 IN THE POST-COVID PERIOD IN PATIENTS WITH CHRONIC HEART FAILURE,"
Central Asian Journal of Medicine: Vol. 2021
, Article 18.
Available at: https://uzjournals.edu.uz/tma/vol2021/iss3/18